deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT02505568

A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease (BEGIN)

An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease

Sponsor: Janssen Korea, Ltd., Korea

Conditions Behcet Disease
Interventions Infliximab
Updated 16 times since 2017 Last updated: Oct 16, 2019 Started: Jul 22, 2015 Primary completion: Jul 13, 2018 Completion: Jul 13, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Behcet Disease, this trial is completed. The trial is conducted by Janssen Korea, Ltd., Korea and has accumulated 16 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Aug 2019 · 9 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Aug 2019 — Nov 2019 [monthly]

    Completed PHASE3

  2. Nov 2018 — Aug 2019 [monthly]

    Completed PHASE3

  3. Oct 2018 — Nov 2018 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  8. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  9. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  10. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  11. Jan 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Korea, Ltd., Korea
Data source: Janssen Korea, Ltd., Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations